TNBC: Adding capecitabine boosts disease-free survival in prospective trialDecember 13, 2019Breast Cancer
APHINITY 6-year data: Benefit ongoing in HER2+ early BC, no significant OS benefitDecember 12, 2019Breast Cancer
Tucatinib called game-changer in HER2-positive metastatic breast cancerDecember 12, 2019Breast Cancer
Trastuzumab deruxtecan has good activity in advanced HER2-positive breast cancerDecember 12, 2019Breast Cancer
